| Name | Title | Contact Details |
|---|
ACTS is a 35-year-old nonprofit based in the Commonwealth of Virginia (U.S.A.) that is supported by all of the worlds leading light car and truck makers. Our mission is to research, educate and promote highway and motor vehicle safety.
With a history of over 25 years, Ceto has forged enduring partnerships with over 2,000 regional and community banks and credit unions nationwide, igniting their profitability and growth. Our unwavering commitment lies in empowering financial institutions with cutting-edge intelligence and transformative solutions, elevating shareholder value, and fostering thriving, prosperous communities. Discover more at ceto.com or dial 866.227.1361 to embark on a transformative journey.
CarbonBuilts Carbon XPrize-winning technology enables the production of ultra low-carbon concrete products, driving gigatonne-scale greenhouse gas reductions through the cost-effective mineralization of carbon dioxide. Our revolutionary approach reduces overall carbon dioxide emissions by 70-100%+, with no compromise on price, performance, or plant operations.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
With headquarters in the greater St. Louis region, UNCOMN provides Industry-Leading B2B Management and Technology Consulting Services. We are a diverse group of engineers, architects, analysts, hackers, and geeks who thrive on finding elegant solutions to wickedly complex organizational, logistic, process, data, and technical problems. In everything we do, we pursue truth, goodness, and beauty. We put people first and hire for the long-term, not for the contract. We put the right people in the right roles. We work with rigor, transparency, and excellence – doing whatever it takes while upholding unquestionable integrity, from start to finish. And we do so with the intention of making our team, clients, and communities better along the way. At UNCOMN, we arent just about profits and the bottom line. We uphold service before self, giving over receiving and social impact over siloing. Its our duty as industry experts to lead by example, share what we know and help create strong, vibrant communities in which we are proud to live and serve. We invest in and mentor for SixThirty CYBER, a business development program that offers cyber security-based technology startups with up to $250,000 of services each year. Through these services, the St. Louis regions top executives and chief information security officers provide hands-on training, mentoring and network opportunities to the startups key stakeholders.